Alnylam Pharmaceuticals (ALNY) Price Target Raised to $500 by H.C. Wainwright

On June 2, H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his price target from $400 to $500. His bullish view reflects confidence in the company’s continued progress across its transthyretin (TTR) amyloidosis portfolio and broader pipeline.

Transthyretin-mediated (ATTR) amyloidosis is a severe and fast-progressing disease caused by a protein called transthyretin (TTR) that doesn’t fold properly. When this happens, the faulty protein builds up in the body as clumps, called amyloid deposits, which can damage the nerves, heart, and digestive system.

A scientist in a biopharmaceutical laboratory examining the development of a product candidate intended to treat a central nervous system disease.

Trucchio highlights the performance of AMVUTTRA (vutrisiran), which has gained meaningful traction since its launch for ATTR amyloidosis with cardiomyopathy (ATTR-CM). He views the rollout as a strong indicator of Alnylam’s ability to deliver commercially and execute on its broader strategy.

The analyst also points to near-term catalysts that could further support the company’s outlook. These include the Phase 2 data from the KARDIA-3 trial evaluating zilebesiran for hypertension, and the recently initiated Phase 3 TRITON-CM study for nucresiran in ATTR-CM. Beyond ATTR, Alnylam’s pipeline includes late-stage candidates in central nervous system, cardiometabolic, and bleeding disorders.

Trucchio believes the company will continue to grow, supported by solid access across payers and strong formulary positioning, and expects these factors to contribute to sustained double-digit revenue expansion.

In the long term, he maintains his view that Alnylam’s TTR franchise alone could generate more than $10 billion in annual revenue, underscoring his bullish stance on the stock.

Alnylam Pharmaceuticals Inc. is an American biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

While we acknowledge the potential of ALNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALNY and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.